The ALPPS in the Treatment of Hepatitis B–Related Hepatocellular Carcinoma With Cirrhosis: A Single-Center Study and Literature Review. (August 2017)

• Record Type: Journal Article
• Authors: Cai, Xiujun; Tong, Yifan; Yu, Hong; Liang, Xiao; Wang, Yifan; Liang, Yuelong; Li, Zheyong; Peng, Shuyong; Lau, W. Y.
• Is Part Of: Surgical innovation. Volume 24:Number 4(2017:Aug.)
• Page Start: 358
• Page End: 364
• Publication Date: 2017-08
• Subjects: ALPPS -- laparoscopy -- tourniquet -- hypertrophy -- future liver remnant; Surgery, Operative -- Periodicals; Endoscopic surgery -- Periodicals; Laparoscopic surgery -- Periodicals; Surgical Procedures, Operative -- Periodicals; Surgical Procedures, Minimally Invasive -- Periodicals; Diffusion of Innovation -- Periodicals; Chirurgie opératoire -- Périodiques; Chirurgie endoscopique -- Périodiques; Chirurgie laparoscopique -- Périodiques; 617.91
• DOI: 10.1177/1553350617697187
• Languages: English
• ISSNs: 1553-3506

Abstract

Background . Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has been reported to be a new treatment strategy for patients with predicted small volumes of future liver remnant (FLR). ALPPS is associated with rapid hypertrophy of FLR but it has a high postoperative mortality and morbidity. Up to now, it is controversial to apply ALPPS in hepatocellular carcinoma, especially for patients with liver cirrhosis. Methods . Between May 2014 and June 2015, consecutive patients who underwent ALPPS with hepatitis B–related hepatocellular carcinoma with cirrhosis carried out in our center were included into the study. Demographic characteristics, surgical outcomes, and pathological results were evaluated. Subsequently, follow-up was still in progress. Results . The median operating time of the first (n = 12) and the second procedures (n = 10) were 285.0 and 212.5 minutes, respectively. The median blood loss were 200 and 800 mL for 2 stages of operations. The severe complication (≥IIIB) rates for the first and the second operations were 25.0% versus 40.0%, respectively. Six patients with too small future live remnant died of postoperative hepatic failure. On a median follow-up of 16 months of the 6 patients discharged, 4 patients were still alive and of 2 were disease-free. Conclusion . In terms of the feasibility and safety, this study showed that ALPPS in the treatment of hepatocellular carcinoma with insufficient future liver remnant might be a double-edged sword, and careful patients selected was proposed. Too small of FLR/SLV, less than 30%, is not recommended for ALPPS in liver with cirrhosis.